CN103083580A - Medical formula - Google Patents
Medical formula Download PDFInfo
- Publication number
- CN103083580A CN103083580A CN2013100592989A CN201310059298A CN103083580A CN 103083580 A CN103083580 A CN 103083580A CN 2013100592989 A CN2013100592989 A CN 2013100592989A CN 201310059298 A CN201310059298 A CN 201310059298A CN 103083580 A CN103083580 A CN 103083580A
- Authority
- CN
- China
- Prior art keywords
- acne
- pharmaceutical formulation
- acid
- mentioned
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medical formula. The medicine comprises pericarpium citri reticulatae, Pinellia ternate, semen coicis and Poria cocos, and has extremely excellent effect for treating acne caused by dysfunction spleen.
Description
Technical field
The present invention relates to a kind of pharmaceutical formulation, belong to biomedicine field.
Background technology
Acne is commonly called as comedo, be chronic inflammation pilosebaceous unit disease, be one of modal disease of department of dermatologry, its morbidity is main and sex hormone level, sebaceous gland are secreted in a large number, propionibacterium acnes propagation, the factor analysis such as the dyskeratosis of pilosebaceous duct and inflammation.Be apt to occur in hebetic masculinity and femininity, the male is slightly more than the women, but women's morbidity is early than the male.Have the teenager of 80%-90% to suffer from acne, often can naturally go down or fully recover after adolescence, individual patient also can extend to more than 30 years old.Although acne is the disease that the spontaneous recovery tendency is arranged, the untimely cicatrix that causes of acne itself and acne treatment can have a strong impact on Quality of Life, causes patient's stress and financial burden, need cause concern.Acne is apt to occur in buccal, forehead, buccal and nasolabial fold, is secondly chest, back and shoulder.
According to international improved method, acne is divided into 4 grades:
1. slight (I level): take acne as main, a small amount of papulopustule, total skin lesion is less than 30;
2. moderate (II level): acne are arranged, the pimple of moderate quatity and pustule, total skin lesion is at 30-50;
3. moderate (III level): a large amount of pimples and pustule, accidental large struvite skin lesion, widely distributed, total skin lesion number is between 51-100, and tuberosity is less than 3;
4. severe (IV level): nodositas, cyst and or the property acne, with pain and form cyst, total skin lesion is more than 100, tuberosity or cyst are more than 3.
Acne is an easily disease of recurrence, and the influence factor is a lot, and single therapy often is difficult to receive good effect, need to take Comprehensive Treatment according to the state of an illness.The common oral drugs of Acne treatment mainly contain:
1. antibiotics: oral antibiotic is one of important method of severe acne in treatment, and selecting the antibiotic for the propionibacterium acnes sensitivity is important starting point, first-selected Tetracyclines, and secondly Macrolide, reach therapeutic effect by suppressing its breeding.
2. tretinoin: oral isotretinoin is the standard treatments of the serious acne such as tuberosity cyst type, aggretion type, and its therapeutic effect is remarkable, but also have teratogenesis, blood fat raises and the side effect such as skin mucosa drying, should use under physician guidance.
3. hormones: the effect to androgen antagonist in pathogenesis of acne, reduce sebum secretion and suppress acne and generate, mainly comprise estrogen and the large class of progestogen two, as cyproterone, ethinylestradiol, diethylstilbestrol etc., also have other antagonism androgens medicines such as spironolactone, cimetidine.
4. glucocorticoid: oral glucocorticoid is mainly used in acne fulminans or acne conglobata, plays the effect of immunosuppressant and antiinflammatory.
5. Chinese patent medicine class: coptos bolus for clearing the upper heat, fangfeng tongsheng pill, danzhi xiaoyao pills, Radix Et Rhizoma Rhei Eupolyphaga seu steleophaga ball, ZHIBAI DIHUANG WAN etc.
Local external use's treatment sterilizes as main take degrease, dissolving cutin, antiinflammatory.Commonly used comprises: tretinoin preparation, benzoyl peroxide, erythromycin, chloromycetin, contain sulfur class lotion etc.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical formulation, the weak point that exists to solve existing Drug therapy acne.
The technical solution used in the present invention is: a kind of pharmaceutical formulation is characterized in that being prepared from by the crude drug of following weight portion:
Pericarpium Citri Reticulatae 3-9 part Rhizoma Pinelliae 3-10 part
Semen Coicis 9-30 part Poria 9-15 part
Above-mentioned raw materials also can adopt extract, for example the commercially available extract of above-mentioned raw materials except adopting former powder.
A kind of pharmaceutical formulation of the present invention, upper on the basis of mentioned component directly or again adds suitable edible or pharmaceutic adjuvant, can make capsule, tablet, granule, oral liquid, powder, teabag etc.
The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic.
Above-mentioned diluent comprises vegetable oil, molecular weight polyethylene glycol 200-6000, the third two liquor-saturated, glycerol, sorbitol, D-xylitol, calcium glycerophosphate, polyvinylpolypyrrolidone, inositol, maltose alcohol, lactobionic acid, cyclodextrin, lactose, calcium oxide, cellulose, glucose, carboxymethyl cellulose, polyvinyl butyral resin etc., and one or more in mineral oil.
Above-mentioned antioxidant comprises one or more in dibenzylatiooluene (BHT), butylated hydroxyarisol (BHA), propyl gallate, tert-butyl hydroquinone (TBHQ), malic acid, glutathion, D-xylose, glycine, a-tocopherol, a-tocopheryl acetate, sodium sulfite, inositol, ascorbic acid, phytic acid, sodium ascorbate, lecithin, hydroquinone, xylitol, succinic acid, tea polyphenols.
Above-mentioned suspending agent comprises one or more in Cera Flava, xanthan gum, arabic gum, casein, methylcellulose, Carboxymethyl cellulose sodium, carbomer, polyvinyl alcohol, hydroxyethyl-cellulose, sodium alginate, chitin, chitose, hydroxypropyl emthylcellulose, ethyl cellulose, agar, hydroxyethylmethyl-cellulose, hyprolose.
Mentioned emulsifier comprises one or more in ethylhydroxyethylcellulose, methylcellulose, glyceryl monostearate, hydroxylated lecithin, the single glycerol vinegar of acetylation, orthoformic acid, casein, ethylene glycol monostearate, diacetyl monoglyceride, acetic acid-fatty acid glycerine vinegar, Emulsifier LM-102, propylene glycol alginate.
Above-mentioned binding agent comprises methylcellulose (MC), polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl emthylcellulose (HPMC), polyvinyl alcohol (PVA), Cellulose Acetate Phthalate (CAP), PVP K30, ethyl cellulose (EC), microcrystalline Cellulose (CC), acrylic resin, Semen Maydis unit, Resina persicae, maltose alcohol, poloxamer; One or more in sodium alginate, liquid glucose, Nulomoline, the acid of sucrose mono laurate.
Above-mentioned disintegrating agent comprises one or more in silica sol, Magnesiumaluminumsilicate, magnesium stearate, pregelatinized starch, cross-linking sodium carboxymethyl cellulose.
Foregoing preservatives comprises one or more in sorbic acid, Sodium Methyl Hydroxybenzoate, benzoic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, P-hydroxybenzoic acid phenyl ester, butyl p-hydroxybenzoate calcium, Oleum Caryophylli, benzyl alcohol, P-hydroxybenzoic acid the third phenol sodium.
Above-mentioned capsule also comprises soft capsule except common gelatin hard-shell capsule.
The specific embodiment
The preparation of embodiment 1. capsules
10 parts of 3 parts of Rhizoma Pinelliaes of Pericarpium Citri Reticulatae
11 parts, 30 parts of Poria of Semen Coicis
Pulverize, cross 100 mesh sieves, encapsulated, granulate, and get final product.
The preparation of embodiment 2. oral liquids
5 parts of 9 parts of Rhizoma Pinelliaes of Pericarpium Citri Reticulatae
15 parts, 21 parts of Poria of Semen Coicis
Add 30 times of amounts of water, be forced into 300Mpa with hyperpressure extraction equipment, pressurize 5 minutes, extracting solution ultrafiltration, concentrated, fill, and get final product.
Claims (3)
1. pharmaceutical formulation is characterized in that being prepared from by the crude drug of following weight portion:
Pericarpium Citri Reticulatae 3-9 part Rhizoma Pinelliae 3-10 part
Semen Coicis 9-30 part Poria 9-15 part.
2. a kind of pharmaceutical formulation as claimed in claim 1, is characterized in that also containing edible or pharmaceutic adjuvant.
3. as any one described a kind of pharmaceutical formulation of claim 1-2, it is characterized in that the former powder of raw material or extract, directly or again add edible or pharmaceutic adjuvant, be prepared into capsule, tablet, granule, oral liquid, powder, teabag etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100592989A CN103083580A (en) | 2013-02-26 | 2013-02-26 | Medical formula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100592989A CN103083580A (en) | 2013-02-26 | 2013-02-26 | Medical formula |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103083580A true CN103083580A (en) | 2013-05-08 |
Family
ID=48197058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100592989A Pending CN103083580A (en) | 2013-02-26 | 2013-02-26 | Medical formula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103083580A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250816A (en) * | 2015-11-10 | 2016-01-20 | 北京市祖国红医疗科技中心（有限合伙） | Medicine composition for treating phlegmatic hygrosis and preparation method and application of medicine composition |
| CN108543044A (en) * | 2018-05-28 | 2018-09-18 | 四川省中医药科学院中医研究所 | A kind of combination medicine and application thereof for treating acne |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152520A (en) * | 2007-09-18 | 2008-04-02 | 尹克山 | Traditional Chinese medicine for treating spleen emptiness and wet sputum type comedo |
-
2013
- 2013-02-26 CN CN2013100592989A patent/CN103083580A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152520A (en) * | 2007-09-18 | 2008-04-02 | 尹克山 | Traditional Chinese medicine for treating spleen emptiness and wet sputum type comedo |
Non-Patent Citations (2)
| Title |
|---|
| 李东光: "《精细化学品配方（六）》", 31 January 2008, 江苏科学技术出版社 * |
| 马素慧等: "解毒祛痘汤治疗寻常痤疮186例", 《陕西中医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250816A (en) * | 2015-11-10 | 2016-01-20 | 北京市祖国红医疗科技中心（有限合伙） | Medicine composition for treating phlegmatic hygrosis and preparation method and application of medicine composition |
| CN108543044A (en) * | 2018-05-28 | 2018-09-18 | 四川省中医药科学院中医研究所 | A kind of combination medicine and application thereof for treating acne |
| CN108543044B (en) * | 2018-05-28 | 2021-05-07 | 四川省中医药科学院中医研究所 | Combined medicine for treating acne and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017372976B2 (en) | Compositions comprising sulfated polysaccharides | |
| Gupta | The efficacy of Euphorbia prostrata in early grades of symptomatic hemorrhoids–a pilot study | |
| CN102085176A (en) | Nanometer itraconazole external preparation and preparation method and use thereof | |
| CN103099904A (en) | Traditional Chinese medicine preparation | |
| CN103083622A (en) | Compound preparation | |
| CN103417683A (en) | Health food capable of reducing blood sugar | |
| CN101804105B (en) | Medicine composition for treating mammitis and preparation method thereof | |
| CN103083580A (en) | Medical formula | |
| CN103099878A (en) | Medicament for treating acne caused by liver qi stagnation | |
| CN103099905A (en) | Spleen deficiency and dampness abundance type acne treatment drug | |
| CN101474192A (en) | Veramyst medicinal preparation and preparation method | |
| CN103099903A (en) | Acne therapeutic preparation | |
| CN103099931A (en) | Pharmaceutical composition | |
| CN103099930A (en) | Preparation for treating acne | |
| CN103908484A (en) | Tripterygium wilfordii plastic for treating rheumatoid arthritis and preparation method thereof | |
| CN103083581A (en) | Medicament for treating spleen deficiency and damp abundance acnes | |
| CN107007614A (en) | The medical usage of cycloastragenol | |
| CN103100062A (en) | Traditional chinese medicine composition | |
| CN104510854B (en) | A kind of Chinese medicine composition for the treatment of dysmenorrhes and uses thereof | |
| CN101152166B (en) | Isoliquirtigenin gelling agent for treating hemorrhoids and method of preparing the same | |
| CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament | |
| CN103110654A (en) | Acne treatment cream | |
| CN101757449B (en) | Ointment preparation for treating hemorrhoid | |
| CN103446288A (en) | Health food for prevention and treatment of diabetes | |
| CN103536810B (en) | Medicament for treating breast hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130508 |